Stomach the News: The Latest Ozempic Lawsuit 2026 Update
Stomach the News: The Latest Ozempic Lawsuit 2026 Update
What You Need to Know Right Now About the Ozempic Lawsuit 2024 Update
The ozempic lawsuit 2024 update marks a turning point in one of the largest pharmaceutical litigations in recent U.S. history. Here is a fast summary of where things stand:
Quick Answer: Ozempic Lawsuit Key Facts
| Topic | Status |
|---|---|
| MDL established | February 2024, Eastern District of Pennsylvania |
| Total cases (April 2026) | 3,546 in MDL 3094 (gastroparesis); 73 in MDL 3163 (vision loss) |
| Main injuries claimed | Gastroparesis, NAION (vision loss), ileus, intestinal obstruction |
| Drugs involved | Ozempic, Wegovy, Mounjaro, Trulicity, Rybelsus |
| Defendants | Novo Nordisk, Eli Lilly |
| Settlements reached | None as of April 2026 |
| Trials expected | Late 2026 or early 2027 at earliest |
Ozempic became a household name almost overnight — first as a diabetes drug, then as a weight loss phenomenon. But behind the headlines, thousands of patients say the drug left them with devastating consequences: stomach paralysis, permanent vision loss, and repeated hospitalizations. Many say they were never warned.
In February 2024, a federal court formally consolidated these claims into a single Multidistrict Litigation (MDL). That decision set the legal machinery in motion. Since then, the case count has exploded — growing from roughly 55 cases at consolidation to more than 3,500 by April 2026. A second MDL was created specifically for vision loss claims.
This is not a small or slow-moving litigation. It is accelerating.
I'm Tim Burd, CEO of Justice Hero, a legal services company that connects injured individuals with the right law firms for medical mass tort cases like this one — and tracking the ozempic lawsuit 2024 update and its aftermath is central to what we do every day. Let's break down exactly what has happened, what it means for you, and what comes next.

Ozempic lawsuit 2024 update terms at a glance:
Understanding the Core Allegations and Injuries
At the heart of the Ozempic litigation is a simple but serious accusation: "failure to warn." Plaintiffs allege that Novo Nordisk and Eli Lilly knew their GLP-1 receptor agonist drugs could cause severe gastrointestinal and vascular issues but chose not to include these risks on the warning labels.

Gastroparesis (Stomach Paralysis)
The most common injury cited in these lawsuits is gastroparesis. This is a condition where the stomach's muscles stop working correctly, preventing it from emptying food into the small intestine. Imagine your digestive system as a highway; gastroparesis is a permanent traffic jam. Patients suffer from chronic vomiting, severe nausea, and malnutrition. Many have reported vomiting undigested food that was eaten days prior. For more details on these symptoms, you can read more about Ozempic issues.
NAION and Vision Loss
A newer and perhaps more frightening development involves NAION (non-arteritic anterior ischemic optic neuropathy). Often called an "eye stroke," NAION occurs when blood flow to the optic nerve is blocked, leading to sudden and often permanent blindness. Recent studies have shown that semaglutide users may have a significantly higher risk of developing this condition compared to those on other medications.
Other Serious Conditions
Beyond stomach paralysis and vision loss, plaintiffs are filing claims for:
- Ileus and Intestinal Blockage: A life-threatening condition where the intestines stop moving, often requiring emergency surgery.
- Gallbladder Disease: Many patients have required the surgical removal of their gallbladder after using these drugs. Check out our Ozempic gallbladder removal complete guide for more information.
- Chronic Vomiting: Some users experience "cyclic vomiting syndrome," which is so severe it can lead to tooth loss from stomach acid and repeated hospitalizations.
Symptoms Comparison: Gastroparesis vs. NAION
| Injury | Primary Symptoms | Impact |
|---|---|---|
| Gastroparesis | Chronic nausea, vomiting undigested food, bloating, abdominal pain | Long-term digestive dysfunction, malnutrition |
| NAION | Sudden, painless vision loss in one eye, blurred vision, loss of peripheral sight | Often permanent blindness or severe visual impairment |
Ozempic Lawsuit 2024 Update: The Foundation of the MDL
The ozempic lawsuit 2024 update is defined by the creation of MDL 3094. In February 2024, the Judicial Panel on Multidistrict Litigation (JPML) decided to consolidate dozens of individual lawsuits into one central location: the Eastern District of Pennsylvania.
This move was vital for the legal process. Instead of thousands of different judges making thousands of different rulings on the same scientific evidence, one court handles all the pretrial work. This includes "Discovery" (where lawyers dig through company emails and documents) and "Science Day."
The Role of Judge Pratter and the Transition
Initially, the late Judge Gene E.K. Pratter presided over the MDL. She oversaw the critical early stages, including the first Science Day in June 2024, where experts explained the biology of GLP-1 drugs to the court. Following her passing, Judge Karen Marston took over the litigation. This transition was a major part of The State of Ozempic Litigation: Important Updates for Summer 2024, ensuring that the momentum of the cases continued despite the judicial change.
Drugs and Defendants
While "Ozempic" is the name most people know, the MDL actually covers a range of similar medications. This includes Novo Nordisk's Wegovy and Rybelsus, as well as Eli Lilly’s Mounjaro and Trulicity. Both pharmaceutical giants are accused of prioritizing profits over patient safety during the massive surge in off-label weight loss prescriptions.
Key Rulings in the Ozempic Lawsuit 2024 Update
The early months of 2024 were packed with procedural milestones that paved the way for the thousands of cases we see today in 2026.
- Centralization (February 2024): This was the official "starting gun." It allowed plaintiffs' attorneys to share resources and expert testimony, making it much harder for pharmaceutical companies to "divide and conquer."
- Master and Short Form Complaints: The court established a streamlined way for new plaintiffs to file. Instead of writing a 100-page lawsuit from scratch, victims can now file a "Short Form Complaint" that checks off their specific injuries while adopting the main legal arguments already established in the "Master Complaint."
- The "Puffery" Defense Ruling: In a significant win for patients, the court rejected the manufacturers' attempts to dismiss the case by claiming their "safe and effective" marketing was just "puffery" (legal talk for harmless exaggeration). The judge ruled that these claims could be scrutinized as part of a failure-to-warn case.
How the Ozempic Lawsuit 2024 Update Shaped Current Claims
The developments in 2024 changed the landscape for every patient in California and beyond. Before 2024, many doctors were unaware that Ozempic could cause permanent stomach paralysis.
In September 2023, the FDA did require an "ileus" (intestinal blockage) warning on the label, but many argue this was too little, too late. The ozempic lawsuit 2024 update focused heavily on the fact that even with these minor updates, the labels still didn't mention "gastroparesis" or "stomach paralysis" clearly enough to warn users of the life-altering risks. This lack of transparency is why so many people are now seeking how much is the Ozempic lawsuit going to payout.
Current Status of the Litigation in 2026
As we sit here in April 2026, the litigation has reached a massive scale. The "small" group of cases from 2024 has grown into a legal mountain.

The Numbers as of April 2026
There are currently 3,546 cases pending in the main GLP-1 MDL (MDL 3094). This represents a staggering increase from the early days of the litigation. Furthermore, a second, separate MDL (MDL 3163) was established specifically to handle the growing number of vision loss (NAION) claims.
According to the Ozempic Lawsuit April 2026 Update, these two tracks are moving forward simultaneously. While the gastroparesis cases are the most numerous, many legal experts believe the NAION cases may actually be stronger because the link between the drug and sudden blindness is becoming harder for the manufacturers to deny.
The FDA Warning Letter (March 2026)
One of the biggest bombshells in the current litigation occurred just last month. In March 2026, the FDA sent a formal warning letter to Novo Nordisk. The agency accused the company of failing to report serious adverse events — including patient deaths — in a timely manner. This is exactly the kind of evidence that can turn a case in favor of the plaintiffs, as it suggests a pattern of withholding safety data from regulators and the public.
What's Next: Bellwether Trials
We are now approaching the "Bellwether" phase. These are a handful of test trials selected to go before a jury. The results of these trials don't legally bind the other 3,500 cases, but they act as a "weather vane." If juries award multi-million dollar verdicts to the first few plaintiffs, it usually forces the pharmaceutical companies to the settlement table. We expect these trials to begin in late 2026 or early 2027.
Qualifying for a Claim and Evidence Needed
If you or a loved one used Ozempic, Wegovy, or Mounjaro and suffered a serious injury, you may be wondering if you qualify for a claim. At Justice Hero, we want to make this as clear as possible.
Eligibility Criteria
To be eligible for the current litigation, most law firms require the following:
- Proof of Use: You must have used a brand-name GLP-1 drug (compounded versions from "med spas" generally do not qualify for these specific lawsuits).
- A Specific Diagnosis: You need a medical diagnosis of gastroparesis, ileus, intestinal obstruction, or NAION.
- Hospitalization: For gastrointestinal claims, many firms look for cases that resulted in an ER visit or hospital stay.
- Objective Testing: For gastroparesis, the court has recently signaled that it prefers "objective" evidence, such as a gastric emptying study (scintigraphy).
For a deeper dive into these requirements, see The Complete Guide To Ozempic Injury Claims And Lawsuit Eligibility.
The Importance of the Statute of Limitations
In California and across the country, there is a limited window of time to file a lawsuit. This is called the "statute of limitations." Generally, the clock starts ticking when you first realize (or should have realized) that the drug caused your injury. Because the ozempic lawsuit 2024 update brought so much public attention to these issues, the "discovery rule" may apply, but you should not wait. If you miss the deadline, you lose your right to compensation forever.
Evidence Checklist
If you are planning to speak with an Ozempic lawsuit lawyer, try to gather these items:
- Pharmacy records showing the dates you filled your prescriptions.
- Medical records from any hospitalizations or ER visits.
- Results of any diagnostic tests (like a gastric emptying scan or eye exams).
- A personal journal or timeline of when your symptoms started and how they affected your daily life.
Our Ozempic Lawsuit Guide 2025 provides a more exhaustive list of how to prepare your case.
Frequently Asked Questions about the Ozempic Lawsuit 2024 Update
What is the current status of the Ozempic MDL?
The litigation is currently in the "Discovery" and "Expert Witness" phase. This means lawyers are gathering evidence and preparing for bellwether trials. There are now two active MDLs: MDL 3094 for gastrointestinal injuries and MDL 3163 for vision loss.
How many cases are currently pending in the Ozempic litigation?
As of April 2026, there are 3,546 cases in the primary MDL. However, legal experts predict this number could eventually reach 10,000 as more people become aware of the link between their symptoms and the medication.
What are the main injuries claimed in Ozempic lawsuits?
The primary injuries are gastroparesis (stomach paralysis), NAION (sudden vision loss), ileus (bowel obstruction), and severe gallbladder disease. Some newer claims also involve deep vein thrombosis (DVT) and pulmonary embolisms.
Conclusion
The road to justice against massive pharmaceutical companies is often long, but the ozempic lawsuit 2024 update laid the groundwork for what is now a powerful movement for corporate accountability. From the initial consolidation in Philadelphia to the recent FDA warnings regarding unreported deaths, the evidence against the makers of these "miracle" drugs continues to mount.
At Justice Hero, we believe that your health should never be a trial run for a corporation's profit margins. If you have suffered because of a lack of warnings on these medications, you have legal rights. We are here to help you navigate this complex process and connect you with the resources you need to hold these companies accountable.
If you’re ready to take the next step, visit our Ozempic Lawsuit page to learn more about how we can support your journey toward justice. We are proud to serve residents across California, including our neighbors in Irvine, as we fight for the transparency and safety every patient deserves.
















